Luminate Medical, a cutting-edge start-up born from the halls of the University of Galway in 2018, is redefining how we approach the painful side effects of chemotherapy.
The company’s innovative wearable medical devices are making waves in the oncology sector, and its groundbreaking solutions have earned it significant recognition, including the coveted Audience Choice Award at the 2022 EIT Health Catapult competition.
Empowering Growth with EIT Health's Support
With EIT Health’s extensive network and resources, Luminate Medical gained access to mentorship, funding guidance, and strategic support, helping the company refine its business strategies and scale its operations across Europe.
Revolutionizing cancer care: From Lily to Lotus
At the heart of Luminate Medical's mission is improving the quality of life for cancer patients. Its flagship product, Lily, a wearable cap designed to prevent chemotherapy-induced hair loss, represents a breakthrough in patient-centered cancer care. Leveraging compression therapy, Lily effectively protects hair follicles from the harmful impact of chemotherapy drugs, preserving not just hair but also a sense of normality and dignity for patients undergoing treatment.
Following Lily’s success, Luminate Medical expanded its portfolio with Lilac, a set of wearable gloves and boots aimed at preventing peripheral neuropathy—a debilitating nerve condition commonly associated with chemotherapy. Now, the company is taking another bold step with the development of Lotus, a device enabling the at-home administration of low-risk anti-cancer drugs, further empowering patients and making treatment more accessible.
This latest round of funding is key to ensuring we can continue making those first steps into the US market. We want to create technologies that make cancer care better, faster and safer for patients. We are incredibly fortunate to have partnered with great investors and advisors who are supporting us in our journey of helping patients live better lives during and after cancer!
Barbara Oliveira, Co-founder of Luminate Medical
A bright future ahead: Funding and expansion
The start-up’s trajectory reached another high point as it secured an additional USD 2.5 M in Series A funding in 2024, bringing the total for this round to USD 17.5 M. The funding extension was led by Atlantic Bridge, with significant contributions from prominent investors such as Finn Murphy of Nebular and Steve Pacelli, former CEO of Nasdaq-listed Dexcom. This fresh injection of capital will support Luminate Medical's growth and accelerate its vision of transforming cancer care. By combining cutting-edge science with patient-first design, the start-up is on a clear path to redefine the oncology landscape.
From its humble beginnings as a university spin-out to winning international accolades and benefiting from the EIT’s robust support network, Luminate Medical exemplifies the power of innovation and collaboration. The company’s journey underscores the importance of fostering groundbreaking solutions to address the most pressing challenges in healthcare.
Share this page
